PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21584513-6	1992	Proximal MDR1 promoter-binding activities of transacting factor were augmented in nuclear extracts from KB cells treated with CPT-11, VM-26, and VP-16.	Irinotecan	126-132	ATP binding cassette subfamily B member 1	Homo sapiens	9-13	
32695000-0	2020	ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients.	Irinotecan	40-50	ATP binding cassette subfamily B member 1	Homo sapiens	0-5	
32695000-5	2020	P-gp is involved in the biliary excretion of irinotecan and its active metabolite SN-38.	Irinotecan	45-55	ATP binding cassette subfamily B member 1	Homo sapiens	0-4	
32695000-5	2020	P-gp is involved in the biliary excretion of irinotecan and its active metabolite SN-38.	Irinotecan	82-87	ATP binding cassette subfamily B member 1	Homo sapiens	0-4	
29861877-5	2018	Contrasting results, however, have been reported on the capability of variants of other genes as MTHFR, TYMS, ERCC1, XRCC1, GSTP1, CYP3A4/3A5 and ABCB1, in predicting either therapy efficacy or toxicity in patients undergoing treatment with pyrimidine antimetabolites, platinum derivatives, irinotecan and taxanes.	Irinotecan	291-301	ATP binding cassette subfamily B member 1	Homo sapiens	146-151	
30925062-5	2019	In addition, the thienopyrimidine could also sensitize ABCB1- as well as ABCG2-overexpressing cells toward daunorubicin and SN-38, respectively, in concentration ranges that qualified it as one of the ten best triple ABCC1/ABCB1/ABCG2 inhibitors in the literature.	Irinotecan	124-129	ATP binding cassette subfamily B member 1	Homo sapiens	55-60	
30925062-5	2019	In addition, the thienopyrimidine could also sensitize ABCB1- as well as ABCG2-overexpressing cells toward daunorubicin and SN-38, respectively, in concentration ranges that qualified it as one of the ten best triple ABCC1/ABCB1/ABCG2 inhibitors in the literature.	Irinotecan	124-129	ATP binding cassette subfamily B member 1	Homo sapiens	223-228	
29499902-1	2018	BACKGROUND AND OBJECTIVES: Evaluate the relationship between the presence of polymorphisms in genes involved in the pharmacodynamics of irinotecan (UGT1A, SLCO1B1, ABCB1 and ABCC2) and the safety of irinotecan in the treatment of metastatic colorectal cancer (mCRC).	Irinotecan	136-146	ATP binding cassette subfamily B member 1	Homo sapiens	164-169	
30135242-3	2018	The hiPSC-IECs showed the transport activities of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and peptide transporter 1 (PEPT1), revealed by using their probe substrates ([3H]digoxin, sulfasalazine, and [14C]glycylsarcosine), and the metabolic activities of CYP3A4, CES2, and CES1, which were clarified using their probe substrates (midazolam, irinotecan, and temocapril).	Irinotecan	364-374	ATP binding cassette subfamily B member 1	Homo sapiens	50-64	
30135242-3	2018	The hiPSC-IECs showed the transport activities of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and peptide transporter 1 (PEPT1), revealed by using their probe substrates ([3H]digoxin, sulfasalazine, and [14C]glycylsarcosine), and the metabolic activities of CYP3A4, CES2, and CES1, which were clarified using their probe substrates (midazolam, irinotecan, and temocapril).	Irinotecan	364-374	ATP binding cassette subfamily B member 1	Homo sapiens	66-70	
29873288-1	2018	BACKGROUND: Irinotecan (IRN) (CPT-11) is a camptothecin derivative with low oral bioavailability due to active efflux by intestinal P-glycoprotein (p-gp) receptors.	Irinotecan	12-22	ATP binding cassette subfamily B member 1	Homo sapiens	132-146	
29873288-1	2018	BACKGROUND: Irinotecan (IRN) (CPT-11) is a camptothecin derivative with low oral bioavailability due to active efflux by intestinal P-glycoprotein (p-gp) receptors.	Irinotecan	24-27	ATP binding cassette subfamily B member 1	Homo sapiens	132-146	
29873288-1	2018	BACKGROUND: Irinotecan (IRN) (CPT-11) is a camptothecin derivative with low oral bioavailability due to active efflux by intestinal P-glycoprotein (p-gp) receptors.	Irinotecan	30-36	ATP binding cassette subfamily B member 1	Homo sapiens	132-146	
31141714-0	2019	Comments on: "Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan".	Irinotecan	93-103	ATP binding cassette subfamily B member 1	Homo sapiens	34-39	
31141715-0	2019	Comments on: "Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan".	Irinotecan	93-103	ATP binding cassette subfamily B member 1	Homo sapiens	34-39	
30213564-0	2018	Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan.	Irinotecan	79-89	ATP binding cassette subfamily B member 1	Homo sapiens	20-25	
30213564-9	2018	Genotyping of ABCB1 variants can help to prevent severe adverse reactions to irinotecan-based treatments in colorectal cancer.	Irinotecan	77-87	ATP binding cassette subfamily B member 1	Homo sapiens	14-19	
27845419-4	2018	rs6498588 (ABCC1) and rs12720066 (ABCB1) were associated with increased SN-38 exposure, and rs17501331 (ABCC1) and rs12720066 were associated with lower absolute neutrophil count nadir.	Irinotecan	72-77	ATP binding cassette subfamily B member 1	Homo sapiens	34-39	
27845419-7	2018	These results suggest that genetic variation in ABCC1 and ABCB1 may contribute to irinotecan-induced neutropenia by altering expression of transporters involved in irinotecan metabolite disposition.	Irinotecan	82-92	ATP binding cassette subfamily B member 1	Homo sapiens	58-63	
27845419-7	2018	These results suggest that genetic variation in ABCC1 and ABCB1 may contribute to irinotecan-induced neutropenia by altering expression of transporters involved in irinotecan metabolite disposition.	Irinotecan	164-174	ATP binding cassette subfamily B member 1	Homo sapiens	58-63	
29016119-5	2017	The best compound was active in a very low micromolar concentration range against all three transporters and restored sensitivity toward daunorubicin (P-gp and MRP1) and SN-38 (BCRP) in A2780/ADR (P-gp), H69AR (MRP1), and MDCK II BCRP (BCRP) cells.	Irinotecan	170-175	ATP binding cassette subfamily B member 1	Homo sapiens	197-201	
26352872-4	2015	MATERIALS AND METHODS: In this study, we aimed to discover toxicity-associated markers in seven transporter genes participating in irinotecan pharmacokinetics involving the ABC transporter genes ABCB1, ABCC1, ABCC2, ABCC5, ABCG1, and ABCG2 and the solute carrier organic anion transporter gene SLCO1B1 and using a haplotype-tagging single-nucleotide polymorphisms (n=210 htSNPs) strategy.	Irinotecan	131-141	ATP binding cassette subfamily B member 1	Homo sapiens	195-200	
27269636-7	2016	Meta-analysis showed an decreased risk of irinotecan-induced neutropenia in patients expressing ABCB1 2677G>T/G (odds ratio [OR]: 0.24; 95% CI: 0.1-0.59; p = 0.002) but increased risk for ABCC2 3972T>T (OR: 1.67; 95% CI: 1.01-2.74; p = 0.04).	Irinotecan	42-52	ATP binding cassette subfamily B member 1	Homo sapiens	96-101	
23850745-1	2013	Irinotecan is a camptothecin derivative with low oral bioavailability due to active efflux by intestinal P-glycoprotein receptors.	Irinotecan	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	105-119	
26692923-6	2015	Lastly, in contrast to both SN-38 (active metabolite of irinotecan) and topotecan are substrates of the efflux pump proteins P-gp/MDR1 and ABCG2/BCRP, FL118 is not a substrate of P-gp and ABCG2.	Irinotecan	28-33	ATP binding cassette subfamily B member 1	Homo sapiens	130-134	
26692923-6	2015	Lastly, in contrast to both SN-38 (active metabolite of irinotecan) and topotecan are substrates of the efflux pump proteins P-gp/MDR1 and ABCG2/BCRP, FL118 is not a substrate of P-gp and ABCG2.	Irinotecan	56-66	ATP binding cassette subfamily B member 1	Homo sapiens	130-134	
26206183-6	2015	Under hypoxic growth condition, ABCG2 and ABCB1-overexpressing cells sorted out by FACS technique as side population (SP) were found to be significantly more responsive to SN-38 (ABCG2 and ABCB1 substrate anticancer drug) in the presence of vatalanib.	Irinotecan	172-177	ATP binding cassette subfamily B member 1	Homo sapiens	42-47	
26206183-6	2015	Under hypoxic growth condition, ABCG2 and ABCB1-overexpressing cells sorted out by FACS technique as side population (SP) were found to be significantly more responsive to SN-38 (ABCG2 and ABCB1 substrate anticancer drug) in the presence of vatalanib.	Irinotecan	172-177	ATP binding cassette subfamily B member 1	Homo sapiens	189-194	
24588516-7	2014	Those results suggest that cetuximab influence irinotecan distribution into tissues probably due to inhibition of P-gp.	Irinotecan	47-57	ATP binding cassette subfamily B member 1	Homo sapiens	114-118	
24588516-9	2014	Inhibiting SN-38 efflux by P-gp drug transporters in biliary system and tumour can lead to pharmacokinetic modification and a higher anticancer efficacy.	Irinotecan	11-16	ATP binding cassette subfamily B member 1	Homo sapiens	27-31	
23953030-3	2013	The canalicular transport of irinotecan and SN-38G is mediated by ABCC2 (MRP2) and ABCB1 (MDR1) which are both inhibited by ciclosporin.	Irinotecan	29-39	ATP binding cassette subfamily B member 1	Homo sapiens	83-88	
23953030-3	2013	The canalicular transport of irinotecan and SN-38G is mediated by ABCC2 (MRP2) and ABCB1 (MDR1) which are both inhibited by ciclosporin.	Irinotecan	29-39	ATP binding cassette subfamily B member 1	Homo sapiens	90-94	
23953030-3	2013	The canalicular transport of irinotecan and SN-38G is mediated by ABCC2 (MRP2) and ABCB1 (MDR1) which are both inhibited by ciclosporin.	Irinotecan	44-49	ATP binding cassette subfamily B member 1	Homo sapiens	83-88	
23953030-3	2013	The canalicular transport of irinotecan and SN-38G is mediated by ABCC2 (MRP2) and ABCB1 (MDR1) which are both inhibited by ciclosporin.	Irinotecan	44-49	ATP binding cassette subfamily B member 1	Homo sapiens	90-94	
25454761-5	2014	Compritol ATO 888 and capmule MCM C8 hybrid lipid mix was employed to prepare irinotecan containing nanostructured lipid carrier (NLC) by using functional excipients with P-gp inhibition activity.	Irinotecan	78-88	ATP binding cassette subfamily B member 1	Homo sapiens	171-175	
25195021-10	2014	In addition, the method has been successfully applied to determine the intracellular accumulation of SN-38 investigating the transport through ABCB1 (P-gp) and ABCG2 (BCRP) efflux pumps in colorectal cancer cell lines.	Irinotecan	101-106	ATP binding cassette subfamily B member 1	Homo sapiens	143-148	
24457609-2	2013	METHODS: We aimed to evaluate the inhibitory potency of gefitinib against the ABCB1- or ABCG2-mediated excretion of CPT-11 and its active metabolite SN-38 in vitro and in vivo.	Irinotecan	116-122	ATP binding cassette subfamily B member 1	Homo sapiens	78-83	
23801203-0	2013	[Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].	Irinotecan	93-103	ATP binding cassette subfamily B member 1	Homo sapiens	16-20	
23801203-1	2013	OBJECTIVE: To investigate the correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer (CRC).	Irinotecan	122-132	ATP binding cassette subfamily B member 1	Homo sapiens	45-49	
23801203-12	2013	CONCLUSION: MDR1 2677 G>T/A may be served as a biomarker in predicting the efficacy of irinotecan chemotherapy in patients with colorectal cancer.	Irinotecan	90-100	ATP binding cassette subfamily B member 1	Homo sapiens	12-16	
24457609-2	2013	METHODS: We aimed to evaluate the inhibitory potency of gefitinib against the ABCB1- or ABCG2-mediated excretion of CPT-11 and its active metabolite SN-38 in vitro and in vivo.	Irinotecan	149-154	ATP binding cassette subfamily B member 1	Homo sapiens	78-83	
23149859-10	2012	After SN-38 was released from TPGS/PLGA/SN-38 NPs in MDR cells, TPGS or/and PLGA may modulate the efflux microenvironment of the P-gp pump, such as mitochondria and the P-gp domain with an ATP-binding site.	Irinotecan	6-11	ATP binding cassette subfamily B member 1	Homo sapiens	129-133	
23149859-10	2012	After SN-38 was released from TPGS/PLGA/SN-38 NPs in MDR cells, TPGS or/and PLGA may modulate the efflux microenvironment of the P-gp pump, such as mitochondria and the P-gp domain with an ATP-binding site.	Irinotecan	6-11	ATP binding cassette subfamily B member 1	Homo sapiens	169-173	
23149859-10	2012	After SN-38 was released from TPGS/PLGA/SN-38 NPs in MDR cells, TPGS or/and PLGA may modulate the efflux microenvironment of the P-gp pump, such as mitochondria and the P-gp domain with an ATP-binding site.	Irinotecan	40-45	ATP binding cassette subfamily B member 1	Homo sapiens	129-133	
23149859-10	2012	After SN-38 was released from TPGS/PLGA/SN-38 NPs in MDR cells, TPGS or/and PLGA may modulate the efflux microenvironment of the P-gp pump, such as mitochondria and the P-gp domain with an ATP-binding site.	Irinotecan	40-45	ATP binding cassette subfamily B member 1	Homo sapiens	169-173	
21459094-10	2011	Inhibition of the drug-efflux pump ABCB1 by PSC-833 allowed irinotecan to eradicate tumor-initiating cells.	Irinotecan	60-70	ATP binding cassette subfamily B member 1	Homo sapiens	35-40	
21787264-6	2011	However, the complex pharmacokinetics of irinotecan and the involvement of several enzymes other than UGT (i.e., carboxyl estherases, CYP450 isoforms), and transmembrane transporters (ABCB1, ABCC1, ABCG2, SLCO1B1) make difficult the identification of patients with an optimal sensitivity and specificity, and a large part of variability among patients still remains unexplained.	Irinotecan	41-51	ATP binding cassette subfamily B member 1	Homo sapiens	184-189	
21459094-15	2011	CONCLUSIONS: The resistance of colorectal tumors to irinotecan requires the cooperative action of tumor-initiating ALDHhigh/ABCB1negative cells and their differentiated, drug-expelling, ALDHlow/ABCB1positive daughter cells.	Irinotecan	52-62	ATP binding cassette subfamily B member 1	Homo sapiens	124-129	
21459094-15	2011	CONCLUSIONS: The resistance of colorectal tumors to irinotecan requires the cooperative action of tumor-initiating ALDHhigh/ABCB1negative cells and their differentiated, drug-expelling, ALDHlow/ABCB1positive daughter cells.	Irinotecan	52-62	ATP binding cassette subfamily B member 1	Homo sapiens	194-199	
19349540-7	2009	Almost 30% of the variability in SN-38 (the active metabolite of CPT-11) AUC is explained by ABCC1 1684T>C, ABCB1 IVS9 -44A>G, and UGT1A1*93 (P = .004).	Irinotecan	65-71	ATP binding cassette subfamily B member 1	Homo sapiens	111-116	
20177420-3	2011	Irinotecan and metabolites are transported by P-glycoprotein, encoded by ABCB1.	Irinotecan	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	46-60	
20177420-3	2011	Irinotecan and metabolites are transported by P-glycoprotein, encoded by ABCB1.	Irinotecan	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	73-78	
20829196-7	2010	Interestingly, multidrug-resistant cell lines that overexpressed P-glycoprotein (P-gp), multidrug resistance-associated proteins, and breast cancer resistance protein were rendered resistant to docetaxel, vinblastine, SN-38, and doxorubicin, but not to I-387.	Irinotecan	218-223	ATP binding cassette subfamily B member 1	Homo sapiens	65-79	
20829196-7	2010	Interestingly, multidrug-resistant cell lines that overexpressed P-glycoprotein (P-gp), multidrug resistance-associated proteins, and breast cancer resistance protein were rendered resistant to docetaxel, vinblastine, SN-38, and doxorubicin, but not to I-387.	Irinotecan	218-223	ATP binding cassette subfamily B member 1	Homo sapiens	81-85	
19771428-3	2010	RESULTS: Higher SN-38 AUC values were observed in ABCB1 2677G>T (A893S) (*2 group) for both regimens.	Irinotecan	16-21	ATP binding cassette subfamily B member 1	Homo sapiens	50-55	
20205661-6	2010	Furthermore variations in the UGT1A gene and the ABCB1 gene influence irinotecan metabolism and disposition.	Irinotecan	70-80	ATP binding cassette subfamily B member 1	Homo sapiens	49-54	
19862647-0	2010	MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer.	Irinotecan	62-72	ATP binding cassette subfamily B member 1	Homo sapiens	0-4	
19862647-0	2010	MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer.	Irinotecan	76-86	ATP binding cassette subfamily B member 1	Homo sapiens	0-4	
19862647-1	2010	The aim of the study was to evaluate the influence of the MDR1 C3435T polymorphism on the therapeutic response in 23 patients treated with cetuximab plus irinotecan for irinotecan refractory liver metastatic colorectal cancer considering their KRAS status.	Irinotecan	154-164	ATP binding cassette subfamily B member 1	Homo sapiens	58-62	
19862647-1	2010	The aim of the study was to evaluate the influence of the MDR1 C3435T polymorphism on the therapeutic response in 23 patients treated with cetuximab plus irinotecan for irinotecan refractory liver metastatic colorectal cancer considering their KRAS status.	Irinotecan	169-179	ATP binding cassette subfamily B member 1	Homo sapiens	58-62	
19862647-2	2010	Indeed, irinotecan and its active metabolite (SN-38) are both substrates of P-glycoprotein (P-gp) encoded by MDR1.	Irinotecan	8-18	ATP binding cassette subfamily B member 1	Homo sapiens	76-90	
19862647-2	2010	Indeed, irinotecan and its active metabolite (SN-38) are both substrates of P-glycoprotein (P-gp) encoded by MDR1.	Irinotecan	8-18	ATP binding cassette subfamily B member 1	Homo sapiens	92-96	
19862647-2	2010	Indeed, irinotecan and its active metabolite (SN-38) are both substrates of P-glycoprotein (P-gp) encoded by MDR1.	Irinotecan	8-18	ATP binding cassette subfamily B member 1	Homo sapiens	109-113	
19862647-2	2010	Indeed, irinotecan and its active metabolite (SN-38) are both substrates of P-glycoprotein (P-gp) encoded by MDR1.	Irinotecan	46-51	ATP binding cassette subfamily B member 1	Homo sapiens	76-90	
19862647-2	2010	Indeed, irinotecan and its active metabolite (SN-38) are both substrates of P-glycoprotein (P-gp) encoded by MDR1.	Irinotecan	46-51	ATP binding cassette subfamily B member 1	Homo sapiens	92-96	
19862647-2	2010	Indeed, irinotecan and its active metabolite (SN-38) are both substrates of P-glycoprotein (P-gp) encoded by MDR1.	Irinotecan	46-51	ATP binding cassette subfamily B member 1	Homo sapiens	109-113	
19862647-9	2010	These results suggest that EGFR inhibition by cetuximab may overcome this irinotecan resistance by abrogating drug efflux depending on MDR1 3435 polymorphism.	Irinotecan	74-84	ATP binding cassette subfamily B member 1	Homo sapiens	135-139	
19349540-7	2009	Almost 30% of the variability in SN-38 (the active metabolite of CPT-11) AUC is explained by ABCC1 1684T>C, ABCB1 IVS9 -44A>G, and UGT1A1*93 (P = .004).	Irinotecan	33-38	ATP binding cassette subfamily B member 1	Homo sapiens	111-116	
17534875-0	2007	Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.	Irinotecan	59-69	ATP binding cassette subfamily B member 1	Homo sapiens	16-21	
18579105-9	2008	The blood to bile distribution ratio (AUC(bile)/AUC(blood)) was significantly reduced after group coadministration of EGCG, it can be seen that the bile efflux transport system of CPT-11 and SN-38 may be markedly reduced by the treatment of EGCG which plays the role of P-gp inhibitor.	Irinotecan	180-186	ATP binding cassette subfamily B member 1	Homo sapiens	270-274	
18579105-9	2008	The blood to bile distribution ratio (AUC(bile)/AUC(blood)) was significantly reduced after group coadministration of EGCG, it can be seen that the bile efflux transport system of CPT-11 and SN-38 may be markedly reduced by the treatment of EGCG which plays the role of P-gp inhibitor.	Irinotecan	191-196	ATP binding cassette subfamily B member 1	Homo sapiens	270-274	
19262372-0	2009	Inhibition of P-glycoprotein-mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposure.	Irinotecan	116-121	ATP binding cassette subfamily B member 1	Homo sapiens	14-28	
19262372-8	2009	SN-38 increased P-gp expression in all cell lines.	Irinotecan	0-5	ATP binding cassette subfamily B member 1	Homo sapiens	16-20	
18558463-6	2008	UGT1A1 *28 homozygosity is strongly associated with irinotecan-induced neutropenia and polymorphisms in the transporting peptides ABCB1 and OATP1B1 have also been associated with gastrointestinal toxicity and irinotecan pharmacokinetics, respectively.	Irinotecan	209-219	ATP binding cassette subfamily B member 1	Homo sapiens	130-135	
18703021-7	2008	A number of Pgp substrates (quinidine, amprenavir, irinotecan, topotecan, atorvastatin and erythromycin) induced net digoxin secretion, as did the non-Pgp substrate artemisinin.	Irinotecan	51-61	ATP binding cassette subfamily B member 1	Homo sapiens	12-15	
17666793-0	2007	Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells.	Irinotecan	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	55-69	
17666793-8	2007	SN-38 decreased p53 expression and increased P-gp expression after 120 h, resulting in inhibition of apoptosis.	Irinotecan	0-5	ATP binding cassette subfamily B member 1	Homo sapiens	45-49	
17666793-10	2007	SN-38-induced P-gp expression was additionally enhanced by p53 decoy oligodeoxynucleotide.	Irinotecan	0-5	ATP binding cassette subfamily B member 1	Homo sapiens	14-18	
17534875-11	2007	CONCLUSIONS: Specific polymorphisms of ABCB1 and ABCC2 can influence disposition and tumor response to irinotecan by regulating transporter activity.	Irinotecan	103-113	ATP binding cassette subfamily B member 1	Homo sapiens	39-44	
16508919-5	2006	Many enzymes are involved in controlling the disposition of irinotecan, including the cellular target (TOP1), metabolism enzymes (CES2, UGT1A1, CYP3A4, CYP3A5), and cellular transporters of the anti-cancer agent (ABCB1, ABCC1, ABCC2, ABCC3, ABCC5, ABCG2).	Irinotecan	60-70	ATP binding cassette subfamily B member 1	Homo sapiens	213-218	
19356014-0	2007	ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.	Irinotecan	139-149	ATP binding cassette subfamily B member 1	Homo sapiens	0-5	
16343744-5	2006	In this review, the role of genetic polymorphisms in the main enzyme-systems (carboxylesterase, cytochrome P450 3A, and uridine diphosphate-glucuronosyltransferase) and ABC-transporters (ABCB1, ABCC2, and ABCG2) involved in irinotecan metabolism, are discussed.	Irinotecan	224-234	ATP binding cassette subfamily B member 1	Homo sapiens	187-192	
15801936-3	2005	All patients were genotyped for allelic variants in genes encoding drug metabolizing enzymes (CYP3A4, CYP3A5, UGT1A1) and drug transporters (ABCB1, ABCC2 and ABCG2) that are involved in irinotecan disposition.	Irinotecan	186-196	ATP binding cassette subfamily B member 1	Homo sapiens	141-146	
16098482-0	2005	MRP1 mutated in the L0 region transports SN-38 but not leukotriene C4 or estradiol-17 (beta-D-glucuronate).	Irinotecan	41-46	ATP binding cassette subfamily B member 1	Homo sapiens	0-4	
16271446-4	2006	Elimination of irinotecan is also dependent on drug-transporting proteins, notably ABCB1 (P-glycoprotein), ABCC2 (cMOAT) and ABCG2 (BCRP), present on the bile canalicular membrane.	Irinotecan	15-25	ATP binding cassette subfamily B member 1	Homo sapiens	83-88	
16132345-3	2005	P-glycoprotein, breast cancer resistance protein, MRP1, and MRP2 have been implicated in resistance to various CPTs including CPT-11 (irinotecan), SN-38 (the active metabolite of CPT-11), and topotecan.	Irinotecan	126-132	ATP binding cassette subfamily B member 1	Homo sapiens	0-14	
16132345-3	2005	P-glycoprotein, breast cancer resistance protein, MRP1, and MRP2 have been implicated in resistance to various CPTs including CPT-11 (irinotecan), SN-38 (the active metabolite of CPT-11), and topotecan.	Irinotecan	134-144	ATP binding cassette subfamily B member 1	Homo sapiens	0-14	
16132345-3	2005	P-glycoprotein, breast cancer resistance protein, MRP1, and MRP2 have been implicated in resistance to various CPTs including CPT-11 (irinotecan), SN-38 (the active metabolite of CPT-11), and topotecan.	Irinotecan	147-152	ATP binding cassette subfamily B member 1	Homo sapiens	0-14	
16132345-3	2005	P-glycoprotein, breast cancer resistance protein, MRP1, and MRP2 have been implicated in resistance to various CPTs including CPT-11 (irinotecan), SN-38 (the active metabolite of CPT-11), and topotecan.	Irinotecan	179-185	ATP binding cassette subfamily B member 1	Homo sapiens	0-14	
15801936-6	2005	The C(max) of irinotecan was significantly lower in patients carrying the CC genotype at exon 26 of the ABCB1 gene compared with those harbouring at least one variant allele (P = 0.047).	Irinotecan	14-24	ATP binding cassette subfamily B member 1	Homo sapiens	104-109	
15801936-8	2005	CONCLUSIONS: The present exploratory study shows that genetic polymorphisms in drug transporter genes, particularly in ABCB1 and ABCG2 genes, may be important in influencing the pharmacokinetics of irinotecan and its metabolites.	Irinotecan	198-208	ATP binding cassette subfamily B member 1	Homo sapiens	119-124	
15801936-9	2005	The predictive value of the identified allelic variants in the ABCG2 and ABCB1 genes on irinotecan disposition should be further investigated in a larger patient population as well as in other ethnic populations.	Irinotecan	88-98	ATP binding cassette subfamily B member 1	Homo sapiens	73-78	
14646693-0	2003	Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan.	Irinotecan	111-121	ATP binding cassette subfamily B member 1	Homo sapiens	22-27	
14646693-0	2003	Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan.	Irinotecan	111-121	ATP binding cassette subfamily B member 1	Homo sapiens	28-32	
12960109-5	2003	The homozygous T allele of the ABCB1 1236C>T polymorphism was associated with significantly increased exposure to irinotecan (P = 0.038) and its active metabolite SN-38 (P = 0.031).	Irinotecan	117-127	ATP binding cassette subfamily B member 1	Homo sapiens	31-36	
12914384-9	2003	MRP2 (multi-drug resistance associated protein) and MDR1 (multi-drug resistance gene) are involved in irinotecan as well as anthracyclines transport.	Irinotecan	102-112	ATP binding cassette subfamily B member 1	Homo sapiens	52-56	
12960109-5	2003	The homozygous T allele of the ABCB1 1236C>T polymorphism was associated with significantly increased exposure to irinotecan (P = 0.038) and its active metabolite SN-38 (P = 0.031).	Irinotecan	166-171	ATP binding cassette subfamily B member 1	Homo sapiens	31-36	
12960109-8	2003	CONCLUSIONS: It is concluded that genotyping for ABCB1 1236C>T may be one of the factors assisting with dose optimization of irinotecan chemotherapy in cancer patients.	Irinotecan	128-138	ATP binding cassette subfamily B member 1	Homo sapiens	49-54	
11395570-4	2001	Both the lactone and carboxylate forms of CPT-11 and SN-38 were actively transported across the cell monolayers, mainly by the apical-localized P-gp pump.	Irinotecan	42-48	ATP binding cassette subfamily B member 1	Homo sapiens	144-148	
11395570-4	2001	Both the lactone and carboxylate forms of CPT-11 and SN-38 were actively transported across the cell monolayers, mainly by the apical-localized P-gp pump.	Irinotecan	53-58	ATP binding cassette subfamily B member 1	Homo sapiens	144-148	
11395570-8	2001	In contrast, SN-38 efficacy decreased in the presence of P-gp inhibitors due to active transport toward the basolateral side, thereby reducing drug accumulation.	Irinotecan	13-18	ATP binding cassette subfamily B member 1	Homo sapiens	57-61	
10912951-4	2000	The etoposide-resistant line with the highest P-gp level was cross-resistant also to SN-38, CPT-11 and topotecan (TPT), but not to 9-aminocamptothecin (9-AC), CPT and DX-8951f.	Irinotecan	85-90	ATP binding cassette subfamily B member 1	Homo sapiens	46-50	
10912951-4	2000	The etoposide-resistant line with the highest P-gp level was cross-resistant also to SN-38, CPT-11 and topotecan (TPT), but not to 9-aminocamptothecin (9-AC), CPT and DX-8951f.	Irinotecan	92-98	ATP binding cassette subfamily B member 1	Homo sapiens	46-50	
9918583-7	1999	These results suggest that MRP and P-gp are involved in the active efflux of SN-38 and CPT-11, respectively, from human KB-derived cells.	Irinotecan	77-82	ATP binding cassette subfamily B member 1	Homo sapiens	35-39	
10378768-13	1999	These findings suggested that an unknown transporter distinct from P-gp, MRP or cMOAT is expressed in KCP-4 cells and transports CPT-11 and SN-38.	Irinotecan	129-135	ATP binding cassette subfamily B member 1	Homo sapiens	67-71	
10378768-13	1999	These findings suggested that an unknown transporter distinct from P-gp, MRP or cMOAT is expressed in KCP-4 cells and transports CPT-11 and SN-38.	Irinotecan	140-145	ATP binding cassette subfamily B member 1	Homo sapiens	67-71	
9918583-7	1999	These results suggest that MRP and P-gp are involved in the active efflux of SN-38 and CPT-11, respectively, from human KB-derived cells.	Irinotecan	87-93	ATP binding cassette subfamily B member 1	Homo sapiens	35-39	
10500811-6	1999	Moreover CPT and SN-38 induced a strong decrease of mdr1 mRNA in MDR treated cells.	Irinotecan	17-22	ATP binding cassette subfamily B member 1	Homo sapiens	52-56	
9472629-6	1998	In contrast to doxorubicin and vincristine, the BRO/mdr1.1 xenografts were at least as sensitive to CPT-11 as the BRO xenografts.	Irinotecan	100-106	ATP binding cassette subfamily B member 1	Homo sapiens	52-56